Keensight Capital, a private equity manager, has acquired a majority stake in regenerative medtech company Isto Biologics from Thompson Street Capital Partners.
Isto Biologics develops and manufactures orthobiologic products to aid the healing process, according to a Sept. 17 news release from Thompson Street Capital Partners.
Keensight will continue to accelerate Isto’s growth strategy through organic expansion and acquisitions.
More than 400 hospitals and clinics, primarily in the U.S., purchase products from Isto Biologics.
Thompson Street Capital Partners will retain a minority stake alongside Isto Biologics’ management team, the release said.
